Skip to main content

Advertisement

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells

Fig. 3

TGFβ induces an EMT-associated kinase switch that promotes erlotinib resistance of CD166+ OSCs. a Tumor cell supernatants of CD166+ and CD166 cells from OS-1 or OS-5 were collected and differential levels of TGFβ production were analyzed by ELISA. Note: Columns, mean of three individual experiments; SD,** P < 0.01. b Immunoblot analysis was performed with antibodies against phosphorylated and total AKT, EGFR and Vimentin, E-Cadherin. GAPDH was used as the control. c With the presence of erlotinib, cell viability of CD166 cells with or without the treatment of TGFβ1 were determined by MTT. Note: Columns, mean of three individual experiments; SD,** P < 0.01. d Phase-contrast images of the ability of tumor spheres formation by seeding with CD166 cells with or without the treatment of TGFβ1 in serum-free medium. Scale bar, 50 μm. e Flow cytometry analysis of CD133 in CD166 cells (from OS-1) without the treatment of TGFβ1

Back to article page